Literature DB >> 21349701

Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway.

Pan Yue1, Zu-Hua Gao, Xia Xue, Shu-Xiang Cui, Cui-Rong Zhao, Yi Yuan, Zhe Yin, Yoshinori Inagaki, Norihiro Kokudo, Wei Tang, Xian-Jun Qu.   

Abstract

Des-γ-carboxy prothrombin (DCP), an aberrant prothrombin produced by hepatocellular carcinoma (HCC) cells, has been shown to be associated with the biological malignant potential of HCC. The aim of this study was to evaluate the effect of DCP on HCC cell growth and metastasis, and to explore the underlying molecular mechanisms. DCP significantly stimulated HCC cell growth, as measured by cell counting kit-8 assay. Transwell chamber assay showed that DCP increased HCC cell migration through reconstituted extracellular matrix (Matrigel). Gelatin zymography assay and Western blot analysis demonstrated that DCP increased the secretion and expression of matrix metalloproteinase (MMP)-2 and MMP-9 in the supernatant of cultured HCC cells and on tumour cell membranes. DCP was found to bind to the cell surface receptor Met, resulting in Met phosphorylation and subsequent activation of the epidermal growth factor receptor (EGFR). Western blot analysis demonstrated that DCP stimulated a sequential kinase phosphorylation cascade including ERK1/2, MEK1/2 and c-Raf, indicating activation of the extracellular signal-regulated kinase/mitogen activated protein kinase (ERK1/2 MAPK) signalling pathway. Furthermore, blocking ERK1/2 MAPK activation with ERK1/2 inhibitor PD98059 essentially abolished the DCP-induced MMP-2 and MMP-9 activity, confirming the signalling pathway of DCP stimulation. Taken together, these results suggested that DCP stimulates HCC growth and promotes HCC metastasis by increasing the activity of MMP-2 and MMP-9 through activation of the ERK1/2 MAPK signalling pathway.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349701     DOI: 10.1016/j.ejca.2011.01.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

Review 2.  Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.

Authors:  Hao Xing; Cunling Yan; Liming Cheng; Nianyue Wang; Shuyang Dai; Jianyong Yuan; Wenfeng Lu; Zhouchong Wang; Jun Han; Yijie Zheng; Tian Yang
Journal:  Tumour Biol       Date:  2016-10-13

3.  Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Authors:  Yi Zhe; Yan Li; Dan Liu; Dong-Ming Su; Jin-Gang Liu; Hang-Yu Li
Journal:  Tumour Biol       Date:  2016-08-04

4.  Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.

Authors:  Zhi Dong; Kun Huang; Bing Liao; Huasong Cai; Yu Dong; Mengqi Huang; Xiaoqi Zhou; Yingmei Jia; Ling Xu; Yanji Luo; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-12-13       Impact factor: 5.315

5.  Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma.

Authors:  Chih H Cheng; Chen F Lee; Tsung H Wu; Kun M Chan; Hong S Chou; Ting J Wu; Ming C Yu; Tse C Chen; Wei C Lee; Miin F Chen
Journal:  World J Surg Oncol       Date:  2011-09-30       Impact factor: 2.754

6.  Different Characteristics of Serum Alfa Fetoprotein and Serum Des-gamma-carboxy Prothrombin in Resected Hepatocellular Carcinoma.

Authors:  Masamichi Hayashi; Suguru Yamada; Nao Takano; Yukiyasu Okamura; Hideki Takami; Yoshikuni Inokawa; Fuminori Sonohara; Nobutake Tanaka; Dai Shimizu; Norifumi Hattori; Mitsuro Kanda; Chie Tanaka; Goro Nakayama; Masahiko Koike; Yasuhiro Kodera
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.406

7.  Role of the exogenous HCV core protein in the interaction of human hepatocyte proliferation and macrophage sub-populations.

Authors:  Zhiyan Yao; Xiaotian Song; Shiru Cao; Wenzhang Liang; Wenran Lu; Lijuan Yang; Zhengzheng Zhang; Lin Wei
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

8.  Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.

Authors:  Shu-Xiang Cui; Wen-Na Shi; Zhi-Yu Song; Shu-Qing Wang; Xin-Feng Yu; Zu-Hua Gao; Xian-Jun Qu
Journal:  Oncotarget       Date:  2016-06-14

Review 9.  Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent.

Authors:  Munechika Enjoji; Daisuke Watase; Kazuhisa Matsunaga; Mariko Kusuda; Nami Nagata-Akaho; Yoshiharu Karube; Jiro Takata
Journal:  Diseases       Date:  2015-07-22

10.  Extracellular HSP70/HSP70-PCs regulate hepatocarcinoma cell migration and invasion via RhoA.

Authors:  Zhe Yi; Yan Li; Dan Liu; Jingang Liu; Hangyu Li
Journal:  Oncol Lett       Date:  2016-12-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.